evipedia.ai
← Back

KP1 for Health & Longevity

Evidence Review created on 10/04/2026 using AI4L / Opus 5.5

Also known as: Klotho-Derived Peptide 1, KP-1

Motivation

KP1 is a short, laboratory-made fragment of Klotho, a protein the body produces mainly in the kidneys and whose blood levels fall as people age. Because the whole protein is large and difficult to turn into a medicine, researchers cut it into overlapping pieces and kept the one that still acted on a signalling route that drives tissue scarring.

Klotho entered aging research in 1997, through a mouse line engineered without the protein. It has since been examined in kidney disease, brain aging and muscle loss, and several groups have tried to raise its levels or copy what it does. KP1 came out of one of those efforts in 2022 and has been examined in rodents and cultured cells; it is sold only as a laboratory reagent.

This review examines what the published work on KP1 does and does not establish: what the peptide is, the pathway it acts on, which effects have been measured and in which systems, what the surrounding literature suggests about harm, and what remains unknown about its use in people.

Benefits - Risks - Protocol - Conclusion

High-level sources that frame KP1 and the Klotho biology it is built from.

Note on priority experts: nothing naming KP1 was found from any priority expert. Rhonda Patrick, Andrew Huberman and Life Extension Magazine mention Klotho only in passing inside broader episodes and articles, which does not meet the depth bar, and Chris Kresser has no Klotho content at all, so nothing from them is listed. The Peter Attia and Lifespan.io items qualify through KP1’s mechanism and therapeutic category instead.

Grokipedia

  • Klotho-derived peptide 1

    Gives the exact sequence, mass and parent residues, the measured receptor affinity, and an unusually blunt commercial section stating KP1 is a research chemical with no approval and no human data.

Examine

No Examine article exists for KP1. Examine covers dietary supplements and does not index unapproved research peptides; a search for the parent protein Klotho also returns nothing.

ConsumerLab

No ConsumerLab article exists for KP1. ConsumerLab tests retail supplement and food products, and no KP1 product is sold through that channel.

Systematic Reviews

No systematic reviews or meta-analyses for KP1 were found on PubMed as of October 2, 2026.

The trade-off at the centre of this review is unrepresented on both sides: there is no systematic review or meta-analysis of KP1’s claimed benefit (reduced organ fibrosis and cell senescence), and none of its principal risk (sustained blockade of transforming growth factor beta signalling).

Mechanism of Action

KP1 is a synthetic 30-amino-acid fragment of the first repeat of human α-Klotho, residues Phe57–Gly86 (as corrected in 2022), mass 3,228 daltons. It binds TGF-β receptor 2 (TβR2 — the docking receptor for transforming growth factor beta, the main signal turning repair cells into scar cells), with a dissociation constant (Kd, the concentration occupying half the receptors) of 1.41 micromolar. Occupying TβR2 blocks transforming growth factor beta, prevents recruitment of its partner receptor, and suppresses both the Smad2/3 message relay and the stress-kinase branch, so fibroblasts make less α-smooth muscle actin (α-SMA, a scar-cell marker), fibronectin and collagen (Yuan et al., 2022 — the discovering group, which stands to gain from KP1’s adoption).

Two further mechanisms are proposed. KP1 raises a cell’s own Klotho protein without changing its messenger RNA, by lowering miR-223-3p (a small RNA that silences Klotho) and raising lncRNA-TUG1 (a long RNA that sponges that silencer) (Zhang et al., 2024). It is also taken into kidney tubule cells, stabilising the mitochondrial protein ATAD3A and limiting cell death (Zhang et al., 2026).

These accounts compete, and the founding work complicates them: KP1 also competes with the body’s own soluble Klotho for TβR2 — interference as much as imitation.

Pharmacology is thin: no half-life, oral availability, selectivity or metabolic route is reported in any species; as a short unmodified peptide it is expected to be cleared by proteases, not liver enzymes (Lee & Poh, 2023). In mice it concentrated in injured kidneys 30 minutes after intravenous injection.

Historical Context & Evolution

Klotho was found by accident. In 1997 a group engineering mice to study blood pressure produced a line lacking a then-unnamed gene; those mice developed hardened arteries, thin bones, emphysema and died at roughly three months instead of thirty (Kuro-o et al., 1997). The gene was named Klotho, and overexpressing it later extended mouse lifespan (Kurosu et al., 2005).

Neither finding concerned a peptide. Klotho’s original role in the literature was as a regulator of phosphate and vitamin D handling, and the short life of the Klotho-deficient mouse has since been read two ways — as a programme of accelerated aging, and as the downstream consequence of phosphate and vitamin D excess. Both readings persist: blocking the tissue calcification that follows the mineral disturbance lengthens those mice’s lives 1.6- to 1.7-fold, with plasma phosphate and calcium left unchanged (Leibrock et al., 2016), which supports the second reading without disposing of the first.

Interest in a short Klotho fragment grew from a practical obstacle rather than a longevity claim. Full-length Klotho is a large membrane protein, hard to manufacture and to deliver, and raising its shed form disturbs mineral handling and bone, while a secreted form did not (Roig-Soriano et al., 2023). Screening eighteen overlapping fragments of the KL1 region (Klotho’s first repeated half) produced KP1 in 2022, developed as a candidate for fibrotic kidney disease. Its appearance in longevity discussion followed from Klotho’s reputation, not from any result in people.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the entire KP1 evidence base is rodent and cell-culture work, so no human clinical endpoint and no validated human surrogate has been measured, in one research group or in several.

Medium 🟩 🟩

No benefit reaches Medium: there is no single human trial of KP1, and no observational human dataset with a comparison group, because no person is known to have been given it under study conditions.

Low 🟩

Suppression of Transforming Growth Factor Beta–Driven Disease ⭕️ Not Central to Health & Longevity

Blocking this pathway helps people, though with another molecule: oral galunisertib improved anaemia in a bone-marrow failure disorder (Santini et al., 2019). Indirect — different compound, class, route and population — so it caps at Low. It bears on whether the target is druggable in humans, not on longevity.

Magnitude: 10 of 41 patients (24.4%) achieved a red-blood-cell response, 95% confidence interval 12.4–40.3 (the range within which the true value most likely lies); single-arm study, no control group.

Speculative 🟨

Reduced Kidney Fibrosis and Kidney Inflammation

In two mouse kidney-scarring models, intravenous KP1 lowered collagen and scar-cell markers, preserved kidney function and reduced immune-cell infiltration (Yuan et al., 2022). Animal and cell-culture basis only; no human data.

Suppression of Cell Senescence and Restoration of Endogenous Klotho

KP1 lowered the cell-aging markers p21, p16 and γ-H2AX in kidney tubule cells of diseased mice while raising the animals’ own Klotho protein (Zhang et al., 2024). Mouse tissue and cultured cells only.

Protection Against Acute Kidney Injury

In mice given platinum chemotherapy or blood-flow interruption, KP1 improved kidney function and reduced tubule-cell death by stabilising a mitochondrial protein (Zhang et al., 2026); a viral-protein model agrees (Xu et al., 2023). Animal only.

Reduced Liver Fibrosis

In Klotho-deficient mice and two models of liver scarring, KP1 reduced collagen deposition and blocked activation of the liver’s scar-forming cells (Tan et al., 2026). Animal and mechanistic evidence only.

Suppression of Cardiac Scar-Cell Activation

In cultured heart fibroblasts from newborn rats, KP1 blocked the scarring signal and reduced scar-cell markers (Yuan et al., 2022). Isolated cells only, with no animal heart outcome — the weakest item here.

Preserved Erectile Function After Nerve Injury

In nerve-injured rats, a Klotho-derived peptide acting on the same receptor preserved erectile function and limited penile fibrosis, oxidative stress and cell death (Xi et al., 2026). Animal and cell work only; an independent group.

Reduced Gut Inflammation and Intestinal Fibrosis

In mice with colitis, oral KP1 inside a cerium-oxide microsphere lowered disease activity, restored gut barrier integrity and cut scar-cell markers (Qiao et al., 2025). Animal only; the composite, not KP1 alone, was tested.

Benefit-Modifying Factors

  • Existing organ injury: In every published model, KP1 concentrated in damaged tissue and acted there; healthy tissue took up little. Benefit is therefore conditional on active scarring, which most of this audience does not have.

  • Baseline Klotho and scarring burden: Effects were reported against a background of depleted Klotho. Where circulating Klotho is already normal, the restoration mechanism has less room to operate, though no study has tested this directly.

  • Sex: All published KP1 animal work used male animals. Raising Klotho by gene transfer produced opposite harm and benefit patterns in male and female mice, so female response to KP1 is entirely unmeasured.

  • Genetic variants: No pharmacogenetic data exist. Variants plausibly relevant include KL-VS (a common Klotho gene variant raising circulating levels) and TGFBR2 (the gene for KP1’s target receptor), but neither has been tested.

  • Age: Klotho falls with age, and aged mice were more vulnerable to the kidney injury KP1 was tested against. Whether an older target reader would respond more, less, or not at all is unknown.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human outcome data of any kind exist for KP1, so no adverse event has been documented in a person, let alone in trials from more than one research group.

Medium 🟥 🟥

No risk reaches Medium: no human trial and no controlled observational dataset has measured any outcome in anyone exposed to KP1, and no harm has been shown for this compound at any dose or in any delivery vehicle.

Low 🟥

Skin Tumours from Transforming Growth Factor Beta Blockade

Neutralising this pathway in people produced reversible keratoacanthomas and squamous-cell carcinomas (locally growing skin cancers) in a first-in-human antibody study (Morris et al., 2014). The pathway restrains tumour growth. Indirect — an antibody neutralising all isoforms, not a receptor-blocking peptide, in cancer patients — capping it at Low.

Magnitude: 4 of 29 patients (13.8%) developed keratoacanthomas or squamous-cell carcinomas; single-arm study, no control group.

Everyday Adverse-Event Burden of Pathway Inhibition

Receptor-kinase inhibition of the same pathway in people produced a low-grade burden of fatigue, diarrhoea, fever and vomiting (Santini et al., 2019). Mismatch of compound, class and population — an oral small molecule against an injected peptide — caps this at Low. Events were mild to moderate, reversible, but common.

Magnitude: grade 1 or 2 adverse events in 20 of 41 patients (49%): fatigue 8/41 (20%), diarrhoea 7/41 (17%), fever 5/41 (12%), vomiting 5/41 (12%); single-arm study, no control group.

Cardiac Valve and Heart-Muscle Toxicity Signal ⚠️ Conflicted

Animal work raised a heart-valve and heart-muscle concern, so human trials of a pathway inhibitor added cardiac surveillance; none found cardiac adverse events (Rodon et al., 2015). Indirect — different compound and class — capping it at Low. Net reading: no human counterpart to the animal signal so far.

Magnitude: no cardiac adverse events in 65 patients under dedicated cardiac surveillance; single-arm study, no control group.

Harm from Unregulated Injectable Peptide Material

Peptides bought outside pharmacy channels carry hazards beyond the molecule: suspected counterfeit injectable semaglutide produced a heavily serious adverse-event profile (Zinzi et al., 2026), and contaminated injectables have caused fever-and-shock reactions from bacterial debris (Johnstone et al., 2018). Indirect — different substances, same channel. KP1 is research grade, sterility untested.

Magnitude: 89.3% of the suspected adverse drug reactions reported across 234 individual case safety reports for suspected counterfeit semaglutide were classed serious; pharmacovigilance series, no control group.

Speculative 🟨

Impaired Wound Healing and Tissue Repair

The blocked signal is central to closing wounds, so sustained blockade would be expected to slow healing after surgery or injury. Mechanistic basis only; no controlled data and no case reports exist for KP1.

Antagonism of the Body’s Own Soluble Klotho

The founding paper reports KP1 competing with endogenous soluble Klotho for the same receptor (Yuan et al., 2022). Where native Klotho is intact, the peptide could displace rather than reinforce it. Mechanistic inference only.

Disturbed Mineral and Bone Metabolism ⚠️ Conflicted

Raising Klotho by gene transfer disturbed phosphate and bone in mice (Roig-Soriano et al., 2023); KP1-treated mice showed unchanged phosphate and calcium (Yuan et al., 2022). The concern is mechanistic, with one measurement against it.

Immunogenicity and Injection-Site Reactions

Any injected synthetic peptide can provoke antibodies against itself or local reactions. No immunogenicity assay has been run on KP1 in any species, so this rests on class reasoning alone.

Risk-Modifying Factors

  • Recent or planned surgery and open wounds: Blocking the repair signal would be expected to matter most when tissue is actively healing. The concern is mechanistic, but it is the clearest modifier of the wound-healing risk above.

  • Personal history of skin cancer: The human harm seen with pathway neutralisation was cutaneous. Pre-existing keratinocyte damage, heavy sun exposure or prior keratoacanthoma plausibly raises that risk, though no study stratified it.

  • Active or prior malignancy: The pathway restrains tumour growth. Registered trials of Klotho-raising therapy exclude people with a cancer history (NCT07285629), which is the nearest sourced exclusion available.

  • Sex: Raising Klotho by gene transfer harmed female mice (skin ulceration, bleeding) while benefiting males. No KP1 study included female animals, so sex-specific risk is unmeasured rather than absent.

  • Age and baseline kidney function: Klotho declines and phosphate handling degrades with age. Older readers, and anyone with reduced kidney function, start closer to the mineral-metabolism concern described above.

  • Genetic variants: No variant has been linked to harm from KP1 or from blocking its target. TGFBR2 variants and the KL-VS Klotho variant are the plausible candidates on mechanism, and neither has been studied for risk.

Key Interactions & Contraindications

Every entry below is theoretical: no interaction study of KP1 has been performed in humans or animals.

  • Antifibrotic drugs (pirfenidone, nintedanib): Caution (theoretical). Both damp the same scarring pathway; combined blockade would be expected to deepen the wound-healing and repair concerns rather than add benefit. No study has combined them.

  • Other pathway inhibitors (galunisertib, fresolimumab): Avoid (theoretical). Overlapping blockade of one target multiplies the skin-tumour and repair risks seen with each agent alone. Mitigation: do not combine; no additive dosing has been studied.

  • Immunosuppressants (ciclosporin, tacrolimus, mycophenolate): Caution (theoretical). The blocked pathway also restrains immune activity and tumour surveillance; adding pharmacological immunosuppression compounds the skin-cancer concern. Mitigation: dermatological surveillance.

  • Systemic corticosteroids (prednisone, dexamethasone): Caution (theoretical). Corticosteroids independently impair wound healing, so the combination would be expected to slow repair further. Mitigation: separate use from any planned surgery.

  • Over-the-counter non-steroidal anti-inflammatory drugs (ibuprofen, naproxen): Monitor (theoretical). These reduce kidney blood flow, and KP1’s only measured organ effects are renal. Mitigation: avoid sustained use; check kidney function if both are used.

  • Supplements reported to damp the same pathway (curcumin, resveratrol): Monitor (theoretical) for additive pathway suppression. Both are described as inhibiting this signal in laboratory systems; no human co-administration data exist with any pathway inhibitor.

  • Supplements and nutrients acting on Klotho (vitamin D, phosphate-containing supplements): Monitor (theoretical). Klotho sits in the phosphate and vitamin D control loop, so changing both at once makes mineral disturbance harder to attribute. Mitigation: hold doses steady.

  • Gene or protein therapies raising Klotho: Avoid (theoretical). Because KP1 competes with soluble Klotho for the receptor, combining them could antagonise rather than add. Nothing in the registry record of such trials (NCT07544420) permits co-administration.

Populations who should avoid KP1:

  • Anyone outside a registered clinical study, since no human dose, route or safety margin has ever been established.
  • People with a history of cancer, autoimmune disease, or chronic kidney or liver disease — the exclusion criteria applied in a registered Klotho-raising interventional study (NCT07285629).
  • Pregnant and breastfeeding people — excluded from that same study; no reproductive toxicology exists for KP1.
  • People with a history of keratoacanthoma or squamous-cell skin cancer, given the cutaneous harm seen with pathway neutralisation (Morris et al., 2014).
  • People on systemic corticosteroids equivalent to ≥20 mg/week prednisone, or on immunosuppressants within two months — thresholds taken from the exclusion criteria of the Phase 1 Klotho messenger-RNA study (NCT07544420).
  • People shortly before or after surgery, or with unhealed wounds, on the mechanistic wound-healing concern; no source gives a numeric interval, so the category is named without one.

Risk Mitigation Strategies

Parameters below follow common practice unless cited; no KP1-specific threshold exists in any source.

  • Confine use to a registered study: The single measure that removes the unquantified risks above is not self-administering an unapproved research chemical. No human dose, route or exposure limit has been established for KP1.

  • Medical supervision with documented baseline: Supervision by a physician who records baseline kidney, liver and mineral labs addresses the mineral-metabolism and kidney concerns, by making a change attributable rather than invisible.

  • Exclusion screening against trial criteria: Screening out cancer history, autoimmune disease and chronic kidney or liver disease mirrors the exclusions in NCT07285629 and targets the tumour-surveillance and organ-function risks.

  • Scheduled skin examination: Full-skin review at baseline and every three to six months targets the keratoacanthoma and squamous-cell carcinoma signal from pathway neutralisation, which was reversible when caught and treated.

  • Avoidance around surgery and wounds: Not using the peptide before planned surgery, dental work, or while a wound is open addresses the impaired-healing concern, which follows directly from the blocked pathway.

  • Independent identity and purity testing: Third-party mass-spectrometry identity and purity testing, plus endotoxin (bacterial debris that causes fever) and sterility assay, addresses the contaminated-material risk, which research-grade supply does not test for.

  • Stop on unexplained change: Stopping on a new skin lesion, unexplained swelling, or a rise in creatinine above the laboratory’s reference range targets the renal and cutaneous risks; no source provides a KP1-specific stopping threshold.

Therapeutic Protocol

No human protocol exists. Parameters below that are not cited reflect common laboratory practice rather than clinical use, and nothing here is a human dose.

  • No established human regimen: No practitioner, clinic or guideline uses KP1, and no dose, route, frequency or duration has been established for people. The figures below are animal laboratory parameters and cannot be converted into a human dose.

  • Published animal regimen, fibrosis models: 1 mg/kg/day in 0.01 M acetic acid, into the tail vein of mice for six consecutive days (Yuan et al., 2022). The same regimen appears in the liver work (Tan et al., 2026).

  • Published animal regimen, distribution study: a single 5 mg/kg intravenous dose of fluorescently tagged peptide, used to track where it went over 30 minutes (Yuan et al., 2022). This was an imaging parameter, not a therapeutic one.

  • Route: Intravenous in all published kidney and liver work. No oral or intranasal study of KP1 exists in any species, and no study reports subcutaneous dosing, so the route used in community peptide practice is unstudied.

  • Competing approaches, gene-based: Raising Klotho by gene transfer or messenger-RNA delivery is the main rival route, with a first human safety study registered, not yet recruiting (NCT07544420); it carries the mineral-metabolism toxicity that motivated fragment work (Roig-Soriano et al., 2023).

  • Competing approaches, non-pharmacological: Exercise raises circulating Klotho in people (Corrêa et al., 2022). It is presented here as the one route to the same target with human evidence behind it, not as a substitute claim for KP1’s specific actions.

  • Best time of day: Unstudied. No circadian, fasting or fed comparison has been made for KP1, and mouse dosing was once daily without a stated time.

  • Half-life: Not reported for KP1 in any species. Short unmodified peptides are typically cleared within minutes to a few hours by proteases (Lee & Poh, 2023), which is why the mouse work dosed daily.

  • Single versus split dosing: Every published experiment used one daily intravenous dose. No split-dose, loading or infusion comparison has been run, so no preference can be stated.

  • Genetic variants influencing dose: None characterised. Variants in TGFBR2, the gene encoding KP1’s target receptor, and the KL-VS Klotho variant are plausible candidates, but no pharmacogenetic study of KP1 exists.

  • Sex differences: Unmeasured. All KP1 animal experiments used male animals, and Klotho-raising gene therapy produced opposite effects by sex in mice, so no dose can be stated for women.

  • Age considerations: Unstudied. Aged mice are more vulnerable to the injuries KP1 was tested against, but no age-stratified dose was examined, and older adults were not represented in any work.

  • Baseline biomarkers influencing response: Peptide accumulation tracked tissue injury, so baseline organ damage plausibly determines local exposure. No study measured a concentration-response relationship against any baseline marker.

  • Pre-existing conditions influencing response: Every reported effect occurred in a diseased organ. In animals without injury there was little uptake and no measured benefit, so response in healthy people is unknown.

Discontinuation & Cycling

  • Course length: Every published course was short — six consecutive days in mice. Whether KP1 would be a short course or a long-term agent in humans is unaddressed, because no chronic-dosing study exists in any species.

  • Withdrawal effects: None reported. No study followed animals after stopping, so rebound scarring, rebound pathway activation, or loss of the restored Klotho after withdrawal are all unmeasured rather than excluded.

  • Tapering: No tapering protocol exists and none is implied by the pharmacology: a peptide cleared within hours leaves no accumulated exposure to step down from. Animals were stopped abruptly with no reported consequence.

  • Cycling: Not studied. No experiment compared continuous with intermittent dosing, so claims that cycling preserves effect or limits risk have no basis in the KP1 literature.

  • Mineral-metabolism follow-up after stopping: Not studied, though it is where follow-up would matter most, since the Klotho restoration KP1 induces sits inside the phosphate control loop.

Sourcing and Quality

  • Research-reagent channel only: KP1 is supplied as a laboratory chemical. Its vendor states plainly, “For research use only. We do not sell to patients.” (Klotho-derived peptide 1). No pharmaceutical-grade source exists anywhere.

  • Named research suppliers: MedChemExpress, Cayman Chemical and Tocris Bioscience catalogue the peptide for laboratory use. These are established research-reagent companies, not pharmacies, and none releases material qualified for administration to people.

  • No compounding pharmacy source: Unlike peptides with an approval history, KP1 has no compounding-pharmacy supply, because there is no approved product or prescribing information for a pharmacist to compound against.

  • Salt form and identity: Supplied as freeze-dried powder, as trifluoroacetate or hydrochloride salt, nominal mass 3,228 daltons. Salt form changes the weighed mass, so the certificate of analysis is where identity and counterion are stated.

  • Purity documentation: Research grade is typically ≥95% pure by high-performance liquid chromatography (HPLC, a separation method that quantifies impurities). That figure describes chemical purity only and says nothing about sterility, endotoxin or residual solvents.

  • Third-party testing: Independent mass-spectrometry identity confirmation plus endotoxin and sterility assay is the only way to characterise what is in a vial, because research supply does not test for the attributes that matter for injection.

Practical Considerations

  • Time to effect: In mice, functional and tissue changes were measured after six to eight days of daily intravenous dosing. No human time course exists, so any expectation of an onset interval in people is unfounded.

  • Common pitfall, name collision: A different and unrelated cosmetic peptide is also marketed as “KP1” (SA1-III) in topical skin creams. Published clinical reports on that ingredient say nothing about the Klotho-derived peptide reviewed here.

  • Common pitfall, borrowed evidence: Results for recombinant Klotho protein, Klotho gene therapy, and the KL-VS gene variant are routinely presented as if they supported this peptide. They concern different molecules, different delivery and different exposure.

  • Common pitfall, route substitution: The published kidney and liver work used intravenous injection. Subcutaneous use, which is how research peptides are typically self-administered, is not reported in any published KP1 study.

  • Regulatory status: KP1 has no marketing authorisation. The US prescribing-information repository holds no label for it (DailyMed label search for klotho, 0 results), and marketing an unapproved new drug for human use is unlawful (Unapproved Drugs).

  • Cost and accessibility: Research vials are cheap beside the Klotho gene therapies competing for the same target. That gap gives insurers and health systems an incentive to favour free exercise over costly Klotho drugs — a plausible bias in what gets funded and recommended.

Interaction with Foundational Habits

  • Sleep: None established, and no mechanism links KP1 to sleep architecture. Short sleep has been associated with lower circulating Klotho in observational work, but nothing connects that to a peptide acting on a scarring receptor, and no study has measured sleep in any KP1 experiment.

  • Nutrition: Indirect and potentially blunting. Klotho sits inside phosphate control, and dietary phosphate load alters α-Klotho expression in rodents (Fukuda-Tatano et al., 2019). Practically, a high-phosphate diet heavy in processed food and cola works against the Klotho restoration KP1 is said to produce.

  • Exercise: Potentiating, on the target rather than on the peptide. Meta-analysis shows exercise raises circulating Klotho in people (Corrêa et al., 2022). No study has combined exercise with KP1, so whether the effects add, overlap or compete at the receptor is unknown.

  • Stress management: Indirect. Chronic psychological stress was associated with lower Klotho in women (Prather et al., 2015). Reducing chronic stress plausibly supports the same endogenous protein, but no KP1 experiment measured stress hormones or behaviour, so no interaction is established.

Monitoring Protocol & Defining Success

Because no human exposure has been studied, monitoring here is safety surveillance, not a success protocol. Before any exposure, a baseline panel establishes what normal looks like for the individual: kidney function, liver enzymes, the mineral pair of phosphate and calcium, and circulating Klotho itself as the one marker the peptide is proposed to move. A full-skin examination belongs at baseline too, since the human harm seen with blockade of this pathway was cutaneous. Ongoing testing would repeat the same panel at four weeks, at three months, then every three to six months, with skin review on the same schedule. Success cannot be defined against an outcome, because no outcome has been measured in people; the honest endpoint is the absence of harm, plus a documented change from the person’s own baseline in Klotho.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum creatinine 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women) (standard reference range) Safety check: kidney function is the organ system every published effect was measured in, and a rise stops use Interpret with estimated glomerular filtration rate (eGFR, a calculated measure of kidney filtering capacity). Affected by muscle mass, creatine supplements and recent heavy exercise
Serum phosphate 2.5–4.5 mg/dL (standard reference range) Safety check: Klotho restoration acts inside phosphate control, and disturbance there is the known toxicity of raising Klotho Draw fasting; levels fall after meals and show a diurnal swing. Pair with calcium
Serum calcium 8.6–10.3 mg/dL (standard reference range) Safety check: completes the mineral pair, since phosphate shifts are interpretable only alongside calcium Correct for albumin, or measure ionised calcium. Best drawn with phosphate in one fasting sample
Alanine aminotransferase (ALT) 7–55 U/L (standard reference range) Safety check: the liver is the second organ with published KP1 effects, and a rise would change or stop use ALT is a liver enzyme released when liver cells are damaged. Draw with aspartate aminotransferase (AST, a related enzyme). Transiently raised by intense exercise and by alcohol
Soluble α-Klotho No established target; track change from the individual’s own baseline Expected to change: raising the body’s own Klotho is the proposed mechanism, so this is the one efficacy marker available Assays are not standardised between laboratories, so use the same laboratory throughout. Lower with age and with reduced kidney function

Qualitative markers worth tracking, none of them validated for this peptide:

  • New or changing skin lesions, scaly growths or sores that do not heal — the one human harm signal with direct evidence behind it for this pathway.
  • Wound-healing speed after minor cuts, dental work or procedures.
  • Fatigue, diarrhoea, fever or vomiting, which made up the everyday burden seen with pathway inhibition in people.
  • Injection-site redness, swelling or persistent nodules.
  • Unexplained swelling of the ankles or face, which would prompt kidney testing.

Emerging Research

  • No registered trial of KP1: ClinicalTrials.gov returns no study of KP1 under any spelling, and no study of any Klotho peptide fragment. Nothing is in the registry to read results from, which is the single most important fact about this peptide’s development stage.

  • Messenger-RNA Klotho replacement, Phase 1: NCT07544420 will give AKL003 or placebo to 21 adults, with adverse-event incidence as the primary endpoint. A clean safety result would make Klotho restoration in people credible; a safety signal would weaken the whole category, peptide fragments included.

  • Klotho and follistatin plasmid gene therapy: NCT07285629 enrolled 14 healthy adults aged 50–80, single-arm, serum Klotho as a primary endpoint. It completed April 2026 with no results posted. Published Klotho elevation would support the target; a null result would undercut the premise.

  • Extension beyond organ fibrosis: Tan et al., 2026 reports KP1 in three liver-scarring models, and an independent group reports the same receptor effect in rat penile tissue (Xi et al., 2026). Further independent replication would show the effect is not laboratory-specific; failure would strip the list back to the kidney.

  • New mechanism, mitochondrial target: Zhang et al., 2026 reports KP1 acting inside cells on the mitochondrial protein ATAD3A rather than only at the receptor. If confirmed, the receptor-blockade account that drives the risk reasoning here is incomplete, in either direction.

  • Oral delivery formulation: Qiao et al., 2025 encapsulated KP1 in cerium-oxide microspheres for gut delivery in mouse colitis. Success would change the route question entirely; failure keeps KP1 an intravenous-only molecule with no practical self-administration path.

  • Evidence that could weaken the case: No study has yet tested whether KP1 displaces the body’s own soluble Klotho at the shared receptor, whether it causes the skin tumours seen with broader pathway blockade, or whether female animals respond as males did. Each is a plausible route to a negative result.

Conclusion

KP1 is a laboratory-made fragment of Klotho, a protein the body makes that declines with age. It was built to block the main scarring signal in tissue, and in mice and cultured cells it reduced scarring in kidney and liver, lowered markers of cell aging, raised the cells’ own Klotho, and protected kidneys from sudden injury. Every one of those findings sits in animals or dishes. Nothing has been measured in a person: no trial, no case series, no published account of anyone taking it. The case for benefit in humans rests entirely on reasoning from animals, and this review grades it accordingly.

The harms are equally unmeasured, which is not the same as absent. Blocking this scarring signal in people, using other drugs built for the purpose, produced skin growths and a common burden of everyday side effects; the signal itself restrains tumour growth and is needed for wounds to close. The peptide is sold only as a research chemical, outside any pharmacy standard for sterility or identity, which adds a hazard separate from the molecule.

Two cautions attach to the evidence itself. Almost all of it comes from the single laboratory that discovered the peptide and stands to gain from its adoption. Much of the surrounding enthusiasm for Klotho comes from parties with a stake: an advocacy foundation funded by donations for this research, and a commentator who discloses investing in a Klotho company. The uncertainty here is close to total.

Top - Benefits - Risks - Protocol